DBV Technologies (DBVT) Research & Development (2020 - 2026)
DBV Technologies (DBVT) posted quarterly Research & Development of $31.2 million for Q2 2026, down 7.42% year-on-year from $33.7 million in Q2 2025, and down 6.59% on a QoQ basis from $33.4 million in Q1 2026.
DBV Technologies (DBVT) Research & Development (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Research & Development for 7 consecutive years, with $31.2 million the latest figure, recorded in Q2 2026.
- Quarterly Research & Development fell 7.42% year-over-year to $31.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $126.1 million (up 28.99% YoY) and the FY2025 annual result came in at $116.7 million, up 30.6% from the prior year.
- Research & Development eased to $31.2 million in Q2 2026 per DBVT's latest filing, from $33.4 million in the prior quarter.
- Over the last five years, Research & Development for DBVT reached as high as $33.7 million in Q2 2025 and fell as low as $12.2 million in Q1 2022.
- A 5-year average of $22.6 million and a median of $21.5 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development surged 153.69% — and 2023, when it sank 56.86%.
- Year by year, Research & Development stood at $29.6 million in 2022, then plunged by 56.86% to $12.8 million in 2023, then soared by 47.98% to $18.9 million in 2024, then soared by 73.99% to $32.9 million in 2025, then dropped by 5.14% to $31.2 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $31.2 million, $33.4 million, and $32.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | 31.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.20 Mn |
| Mar 31, 2026 | 33.40 Mn |
| Dec 31, 2025 | 32.89 Mn |
| Sep 30, 2025 | 28.62 Mn |
| Jun 30, 2025 | 33.70 Mn |
| Mar 31, 2025 | 21.50 Mn |
| Dec 31, 2024 | 18.90 Mn |
| Sep 30, 2024 | 23.66 Mn |
| Jun 30, 2024 | 25.37 Mn |
| Mar 31, 2024 | 21.40 Mn |
| Dec 31, 2023 | 12.78 Mn |
| Sep 30, 2023 | 13.80 Mn |
| Jun 30, 2023 | 17.62 Mn |
| Mar 31, 2023 | 16.04 Mn |
| Dec 31, 2022 | 29.61 Mn |
| Sep 30, 2022 | 15.10 Mn |
| Jun 30, 2022 | 18.61 Mn |
| Mar 31, 2022 | 12.22 Mn |
| Dec 31, 2021 | 11.67 Mn |
| Sep 30, 2021 | 16.32 Mn |